Deal overview
| Target | AVEXIS INC |
|---|---|
| Bidder | NOVARTIS AG |
| Price | £0.00 Full version or £25.00 Light version |
| Publication Date | Apr 09, 2018 |
| Abstract | On 9 April 2018, the quoted Swiss pharmaceutical group Novartis AG ("Novartis") announced a recommended offer for AveXis Inc ("AveXis"), a US-listed clinical-stage gene therapy company. The offer of $218 in cash per share valued 100% of AveXis at $8.65 billion. Completion of the transaction was expected in mid-2018, pending the successful completion of the offer and all ... |
| Number of pages (Full version) | 0 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
